Evidence map›Paper›PMID 41524404›Full record

ArticlemBio2026

Development and evaluation of novel zein-based artemisinin sustained-release formulation for treating drug-resistant malaria.

Yijie Wang, Xinyu Yu, Xinyu Zhang, Xiaohui He, Yongxin Tang, Ling Fang, Richard Culleton, Qingfeng Zhang, Weifu Dong, Jun Cao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yijie Wang *The Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi, China.ORCID 0009-0005-3090-2018
Xinyu Yu *Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0002-1339-3558
Xinyu Zhang *Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Xiaohui HeNational Health Commission Key Laboratory of Parasitic Disease Control and Prevention, Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Jiangsu Institute of Parasitic Diseases, Wuxi, China.
Yongxin TangCenter for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Ling FangNational Health Commission Key Laboratory of Parasitic Disease Control and Prevention, Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Jiangsu Institute of Parasitic Diseases, Wuxi, China.
Richard CulletonDivision of Parasitology, Proteo-Science Centre, Ehime University, Matsuyama, Ehime, Japan.
Qingfeng ZhangLaboratory of Molecular Parasitology, State Key Laboratory of Cardiology and Research Center for Translational Medicine, Shanghai East Hospital; Clinical Center for Brain and Spinal Cord Research, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-8759-9102
Weifu DongThe Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi, China.ORCID 0000-0002-7432-8362
Jun CaoCenter for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0001-5298-9234

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artemisinin antimalarial drugs initially exhibited remarkable efficacy against IMPORTANCE: Half of the world's population is at risk of malaria infection, and artemisinin (ART) turns out to be a powerful medicine for malaria control. The rapid emergence and global spread of resistance to ART have led to a significantly increasing clinical treatment failure rate worldwide. A critical limitation of ART is its extremely short blood half-life (~1 h), which results in rapid declines in plasma drug concentrations below therapeutic thresholds. Some parasites may switch into a "dormant" form, which is less sensitive to ART, resulting in recrudescence following treatment. Thus, developing a sustained-release formulation provides a promising solution to prolong the

Indexed as

AntimalarialsArtemisininsDelayed-Action PreparationsDrug ResistanceMalariaPlasmodium falciparumZeinAnimalsDisease Models, AnimalDrug CarriersFemaleHumansMiceNanoparticlesAntimalarialsartemisininArtemisininsDelayed-Action PreparationsDrug CarriersZeinartemisinin resistancePlasmodiumsustained releasezein-based nanoparticle

Identifiers

PMID41524404
PMCPMC12892940

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.